Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.

June 1, 2023

Sandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone company

The Sandoz AG headquarters plans to move to a landmark office building called “Elsässertor” in the center of Basel, right by the Basel SBB train station. Sandoz expects to move from the Novartis Campus to its new headquarters in mid-2024.

Read the full media release

May 15, 2023

New Sandoz Board of Directors appointed

Sandoz takes the next steps to prepare for the planned listing on the Swiss Stock Exchange (SIX): The Novartis Board of Directors has approved the recommendations of the Sandoz Chairman-designate, Gilbert Ghostine, on the structure of the to-be Board of Directors of Sandoz and has nominated all of its future members.

Read the full media release

April 25, 2023

Sandoz planned spin-off updates at Novartis Q1 2023 Financial Results

The planned spin-off remains on track for the second half of 2023. Completion of the transaction is subject to certain conditions, including consultation with works councils and employee representatives (as required), general market conditions, tax rulings and opinions, final Board of Directors endorsement and shareholder approval in line with Swiss corporate law. The transaction is expected to be tax neutral to Novartis.

Read the full media release

Sandoz Capital Markets Day for investors will take place on June 8, 2023 (New York, USA) and June 12, 2023 (London, UK)

Feb 20, 2023

Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors

Read the full media release: English

Aug 25, 2022

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off

Read the full media release: English | German


Watch the webcast
16:00 CEST | 15:00 BST | 10:00 EDT

Download the presentation (PDF 1.1 MB)

Additional resources

Sandoz is a global leader in generic pharmaceuticals and biosimilars. Our purpose is pioneering novel approaches to help people around the world access high-quality medicine.

Learn more